{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:48:40Z","timestamp":1772945320373,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":58,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20231018"],"award-info":[{"award-number":["20231018"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aohep.2025.102106","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:16:14Z","timestamp":1756649774000},"page":"102106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined as a comprehensive treatment for hepatocellular carcinoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Bingzheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.aohep.2025.102106_bib0001","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1002\/cam4.5931","article-title":"The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"12","author":"Shimose","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.aohep.2025.102106_bib0002","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12328-023-01777-y","article-title":"A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments","volume":"16","author":"Tomonari","year":"2023","journal-title":"Clin J Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2025.102106_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"10.1016\/j.aohep.2025.102106_bib0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cam4.4854","article-title":"Does first-line treatment have prognostic impact for unresectable HCC?-atezolizumab plus bevacizumab versus lenvatinib","volume":"12","author":"Hiraoka","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.aohep.2025.102106_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000519749","article-title":"A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver cancer"},{"issue":"17","key":"10.1016\/j.aohep.2025.102106_bib0006","first-page":"8119","article-title":"Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus","volume":"27","author":"Tan","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.aohep.2025.102106_bib0007","article-title":"Adrenocortical carcinoma with tumor thrombus extension into the right atrium","volume":"133","author":"Szmyt","year":"2023","journal-title":"Pol arch intern med"},{"issue":"16","key":"10.1016\/j.aohep.2025.102106_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14164028","article-title":"Targeted therapy for hepatocellular carcinoma: old and new opportunities","volume":"14","author":"Laface","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.aohep.2025.102106_bib0009","doi-asserted-by":"crossref","first-page":"e7410","DOI":"10.1002\/cam4.7410","article-title":"CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.aohep.2025.102106_bib0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/hepr.13734","article-title":"Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - multicenter analysis","volume":"52","author":"Hiraoka","year":"2022","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2025.102106_bib0011","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.2147\/IJN.S390384","article-title":"Non-viral gene delivery to hepatocellular carcinoma via intra-arterial injection","volume":"18","author":"Vaughan","year":"2023","journal-title":"Int J Nanomed"},{"issue":"11","key":"10.1016\/j.aohep.2025.102106_bib0012","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.aohep.2025.102106_bib0013","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3177\/jnsv.60.357","article-title":"Combination of bevacizumab and acyclic retinoid inhibits the growth of hepatocellular carcinoma xenografts","volume":"60","author":"Kubota","year":"2014","journal-title":"J Nutr Sci Vitaminol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102106_bib0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40644-019-0266-9","article-title":"Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma","volume":"19","author":"Jiang","year":"2019","journal-title":"Cancer Imaging: Off Publ Int Cancer Imaging Soc"},{"issue":"2","key":"10.1016\/j.aohep.2025.102106_bib0015","first-page":"134","article-title":"[Clinical efficacy and prognostic factors analysis following curative hepatectomy for hepatocellular carcinoma patients with different China Liver Cancer Staging]","volume":"59","author":"Li","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"3","key":"10.1016\/j.aohep.2025.102106_bib0016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1148\/radiol.2015142140","article-title":"Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of Bevacizumab or a Placebo","volume":"277","author":"Pinter","year":"2015","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.aohep.2025.102106_bib0017","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102106_bib0018","doi-asserted-by":"crossref","first-page":"10571","DOI":"10.1038\/s41598-020-65012-1","article-title":"Hybrid modelling of transarterial chemoembolisation therapies (TACE) for hepatocellular carcinoma (HCC)","volume":"10","author":"Perfahl","year":"2020","journal-title":"Sci Rep"},{"issue":"10127","key":"10.1016\/j.aohep.2025.102106_bib0019","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Bruix J: hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.102106_bib0020","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"10.1016\/j.aohep.2025.102106_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.aohep.2025.102106_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.aohep.2025.102106_bib0023","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.exphem.2006.04.002","article-title":"Mutual, reciprocal SDF-1\/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD\/SCID chimeric mice","volume":"34","author":"Dar","year":"2006","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102106_bib0024","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","article-title":"Targeting SDF-1 in multiple myeloma tumor microenvironment","volume":"380","author":"Bouyssou","year":"2016","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.aohep.2025.102106_bib0025","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.aohep.2025.102106_bib0026","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.aohep.2025.102106_bib0027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/kjm2.12822","article-title":"Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung","volume":"40","author":"Kuo","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"issue":"8","key":"10.1016\/j.aohep.2025.102106_bib0028","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.bjps.2020.11.041","article-title":"HIF-1\u03b1 inhibits mitochondria-mediated apoptosis and improves the survival of human adipose-derived stem cells in ischemic microenvironments","volume":"74","author":"Wang","year":"2021","journal-title":"J Plast Reconstr Aesthet Surg: JPRAS"},{"key":"10.1016\/j.aohep.2025.102106_bib0029","doi-asserted-by":"crossref","first-page":"783574","DOI":"10.3389\/fonc.2021.783574","article-title":"Transarterial chemoembolization combined with endoscopic therapy is beneficial for unresectable hepatocellular carcinoma with esophagogastric varices","volume":"11","author":"Tao","year":"2021","journal-title":"Front Oncol"},{"issue":"Pt 2","key":"10.1016\/j.aohep.2025.102106_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin, Cancer Biol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102106_bib0031","first-page":"310","article-title":"Potential novel ovarian cancer treatment targeting myeloid-derived suppressor cells","volume":"39","author":"Abiko","year":"2021","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.aohep.2025.102106_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-060955","article-title":"Protocol of notable-HCC: a phase ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2022","journal-title":"BMJ open"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S166526812500331X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S166526812500331X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:05:32Z","timestamp":1772892332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S166526812500331X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S166526812500331X"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102106","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined as a comprehensive treatment for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102106"}}